References
- Miller DW, Feldman SR. Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opin Pharmacother. 2006;7:157–167.
- Simpson GL, Yelverton CB, Rittenberg S, Feldman SR. Do utilization management controls for phototherapy increase the prescription of biologics? J Dermatolog Treat. 2006;17:359–361.
- Simpson JF, Yelverton CB, Balkrishnan R, Fleischer A Jr, Lide W, Feldman SR. Would elimination of copayments for phototherapy decrease the cost of treating psoriasis with systemic biologics? A cost analysis. Manag Care Interface. 2006;19:39–43.
- Tristani-Firouzi P, Krueger GG. Efficacy and safety of treatment modalities for psoriasis. Cutis. 1998;61:11–21.
- Feldman SR, Koo JY, Lebwohl MG, Menter A, Van Voorhees A. The psoriasis and psoriatic arthritis pocket guide: Treatment algorithms and management options. Portland, OR: National Psoriasis Foundation; 2005.
- Housman TS, Rohrback JM, Fleischer AB Jr, Feldman SR. Phototherapy utilization for psoriasis is declining in the United States. J Am Acad Dermatol. 2002;46:557–559.